Every 10-Q that Dexcom Inc (DXCM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DXCM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DXCM filings page.
DexCom generated strong results for the quarter ended June 30, 2026, with revenue of $1,308.4 million, up 13% year over year, and gross profit of $830.0 million, raising gross margin to 63.4% from 59.5%. Operating income rose to $318.3 million (up 50%), and net income to $249.1 million (up 39%), or $0.64 diluted EPS, driven mainly by higher disposable sensor volumes, continued expansion of the worldwide customer base, and favorable revenue per customer, partly offset by channel/product mix, rebate eligibility, and higher inventory reserves tied to the planned discontinuation of G6 manufacturing.
For the first six months of 2026, revenue reached $2,500.3 million (up 14%) and net income $448.6 million (up 57%), as G7 15 Day benefits, improved manufacturing efficiencies, higher production volumes and a more favorable manufacturing mix lifted margins despite larger excess and obsolete inventory charges of $84.2 million. Operating cash flow was $794.8 million, and DexCom ended the period with $1.95 billion in cash, cash equivalents and short-term marketable securities. Capital allocation included repurchasing 8.6 million shares for $600.0 million under the 2026 Share Repurchase Program, while maintaining $1.25 billion of 0.375% senior convertible notes due 2028 and an undrawn $200.0 million revolving credit facility (aside from $8.7 million in letters of credit).
Dexcom delivered strong Q3 2025 results, led by higher disposable sensor volumes. Revenue reached $1,209.3 million, up 22% year over year, with gross profit of $731.4 million and operating income of $242.5 million. Net income rose to $283.8 million, and diluted EPS was $0.70, compared to $0.34 a year ago.
Margins benefited from higher manufacturing volumes and lower legal expenses, partially offset by pricing headwinds and production inefficiencies. Other income improved on gains from equity investments. Operating cash flow was $659.9 million for the quarter, supporting a strong liquidity position; cash, cash equivalents and short‑term marketable securities totaled $3.32 billion at quarter end.
The company repurchased 2.4 million shares for $187.2 million under its $750 million authorization. U.S. revenue was $851.9 million (70% of total), with International at $357.4 million (30%). Dexcom noted a tax benefit from its Malaysia tax holiday. Convertible notes outstanding remained at $2.46 billion principal with low coupons, and no conversions were reported.